Retatrutide 32 Pen

Retatrutide (LY3437943) is an investigational triple-receptor agonist research peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It is among the most mechanistically complex metabolic research peptides currently in clinical evaluation. BodyPharm supplies Retatrutide strictly for qualified laboratory research.

BodyPharm sells Retatrutide strictly for research purposes. Customers are responsible for understanding applicable regulations in their jurisdiction.

Phase 2 clinical trial data published in The New England Journal of Medicine (2023) showed mean body weight reductions of approximately 17.5% at 24 weeks in participants receiving the highest studied dose. Preliminary findings also indicate significant reductions in hepatic fat fraction, making Retatrutide a subject of growing research interest in NAFLD/MASH models.

BodyPharm is a UAE-based research peptide supplier offering Retatrutide for laboratory use with same-day delivery across Dubai, Abu Dhabi, and the wider UAE. Each pen is independently verified at 99% or higher purity by Janoshik analytical laboratory.

Research-grade Retatrutide should be stored refrigerated at 2 to 8 degrees Celsius in a controlled laboratory environment. Minimise exposure to heat, light, and repeated freeze-thaw cycles to preserve compound integrity.